AR036672A1 - Derivados de pirrolidinona - Google Patents
Derivados de pirrolidinonaInfo
- Publication number
- AR036672A1 AR036672A1 ARP020103733A ARP020103733A AR036672A1 AR 036672 A1 AR036672 A1 AR 036672A1 AR P020103733 A ARP020103733 A AR P020103733A AR P020103733 A ARP020103733 A AR P020103733A AR 036672 A1 AR036672 A1 AR 036672A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycle
- alkynyl
- cycloalkyl
- alkenyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Composiciones farmacéuticas y compuestos útiles en el tratamiento de condiciones mediadas por CCR2, MCP-1 o la interacción de los mismos. Los compuestos son pirrolidinonas y pirrolidin-tionas. Reivindicación 1: Una composición farmacéutica que comprende un compuesto conforme a la fórmula (1), en donde: Y es oxígeno o azufre; G y G', junto con el enlace que los une, son HC-CH o C=C; V es arilo, heterociclo o cicloalquilo; Z es halógeno, alquilo, alquenilo, alquinilo, hidroxilo, amino, alcoxi, ariloxi, nitro o ciano; R1 es hidrógeno, halógeno, alquilo, cicloalquilo, alquenilo, cicloalquenilo, alquinilo, arilo o heterociclo; R2 es hidrógeno o hidroxilo; R3 es -C(O)R3a, -C(O)OR3a, -C(O)N(R3a)(R3b), -S(O)2R3a, -S(O)R3a ó -SR3a, donde R3a y R3b tienen, independientemente, el mismo significado que R1; R4 es hidroxilo, sulfanilo o amino; t es 0, 1, 2, 3, 4 ó 5; o una sal farmacéuticamente aceptable o degradable metabólicamente derivada del mismo, junto con un diluyente o vehículo farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97014001A | 2001-10-03 | 2001-10-03 | |
US40080702P | 2002-08-01 | 2002-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036672A1 true AR036672A1 (es) | 2004-09-22 |
Family
ID=27017198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020103733A AR036672A1 (es) | 2001-10-03 | 2002-10-03 | Derivados de pirrolidinona |
Country Status (19)
Country | Link |
---|---|
US (3) | US20050004180A1 (es) |
EP (1) | EP1434577A1 (es) |
JP (1) | JP2005523238A (es) |
KR (1) | KR20040048936A (es) |
CN (1) | CN1564685A (es) |
AR (1) | AR036672A1 (es) |
BG (1) | BG108660A (es) |
BR (1) | BR0212968A (es) |
CA (1) | CA2463198A1 (es) |
CO (1) | CO5390075A1 (es) |
CZ (1) | CZ2004442A3 (es) |
HU (1) | HUP0402503A2 (es) |
IL (1) | IL160642A0 (es) |
MX (1) | MXPA04002982A (es) |
NO (1) | NO20041767L (es) |
NZ (1) | NZ532018A (es) |
PL (1) | PL370355A1 (es) |
RU (1) | RU2004109818A (es) |
WO (1) | WO2003030897A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0211750A (pt) * | 2001-08-10 | 2004-10-13 | Shionogi & Co | Agente antiviral |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7220356B2 (en) * | 2002-09-13 | 2007-05-22 | Biogen Idec Inc. | Method of purifying polypeptides by simulated moving bed chromatography |
CN1956976A (zh) * | 2004-05-26 | 2007-05-02 | 詹森药业有限公司 | 作为ccr2受体拮抗剂的巯基咪唑化合物 |
BRPI0511599A (pt) * | 2004-05-26 | 2008-01-02 | Janssen Pharmaceutica Nv | mercaptoimidazóis como antagonistas receptores de ccr2 |
RU2007108289A (ru) * | 2004-08-11 | 2008-09-20 | Янссен Фармацевтика Н.В. (Be) | Меркаптоимидазолы, предназначенные для использования в качестве антагонистов рецептора ccr2 |
US20080187508A1 (en) * | 2004-09-08 | 2008-08-07 | Boys Town National Research Hospital | Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12 |
US20090012148A1 (en) * | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
US20100069380A1 (en) * | 2006-09-22 | 2010-03-18 | Soongyu Choi | Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
US8278345B2 (en) * | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AR065369A1 (es) | 2007-02-19 | 2009-06-03 | Novartis Ag | Derivados de ciclohexil - amida del acido aril- carboxilico |
WO2008103367A2 (en) * | 2007-02-20 | 2008-08-28 | Sergey Kozmin | Method for assembling high-purity chemical libraries, proapoptotic compounds discovered by same |
CA2682473A1 (en) | 2007-03-30 | 2008-10-09 | Shionogi & Co., Ltd. | Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
FR2929851B1 (fr) * | 2008-04-09 | 2012-11-30 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
WO2010035727A1 (ja) * | 2008-09-25 | 2010-04-01 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
AU2010270152A1 (en) * | 2009-07-10 | 2012-02-02 | Vivalis | 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis C NS5B polymerase, the pharmaceutical composition thereof and their therapeutic use |
EP2451453A1 (en) * | 2009-07-10 | 2012-05-16 | Vivalis | Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use |
SG183229A1 (en) | 2010-03-10 | 2012-09-27 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2012093174A1 (en) | 2011-01-07 | 2012-07-12 | Vivalis | 1-(6-membered azo-heterocyclic)-2,5-dihydro-1h-pyrrol-2-one derivatives as anti-hepatitis c virus, the pharmaceutical composition thereof and their therapeutic use |
US9493412B2 (en) | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013049096A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2760829B1 (en) | 2011-09-27 | 2016-05-18 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
NZ718708A (en) | 2012-12-21 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US9682085B2 (en) * | 2013-02-22 | 2017-06-20 | Shifa Biomedical Corporation | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases |
CN105228616B (zh) * | 2013-03-15 | 2019-05-03 | 实发生物医学公司 | 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型(抗PCSK9)化合物及其用于治疗和/或预防心血管疾病的方法 |
WO2014157047A1 (ja) * | 2013-03-27 | 2014-10-02 | 千葉県 | 神経変性疾患治療剤 |
WO2015004610A1 (en) | 2013-07-11 | 2015-01-15 | Adamed Sp. Z O.O. | 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction |
HUE037347T2 (hu) | 2013-07-12 | 2018-08-28 | Gilead Sciences Inc | Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
SI3277691T1 (sl) | 2015-04-02 | 2019-04-30 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
KR102370515B1 (ko) | 2016-06-21 | 2022-03-03 | 시파 바이오메디칼 코포레이션 | 항-프로단백질 전환효소 서브틸리신 켁신 유형 9(항-pcsk9) 화합물 및 심혈관 질환의 치료 및/또는 예방에 이를 사용하는 방법 |
CN114262290B (zh) * | 2021-12-20 | 2024-03-22 | 华东师范大学 | 一类4-亚甲基吡咯烷-2-硫酮类化合物及其合成方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4988864A (es) * | 1972-12-29 | 1974-08-24 | ||
SU1114676A1 (ru) * | 1983-03-31 | 1984-09-23 | Пермский государственный фармацевтический институт | 1,5-Дифенил-3-окси-4-метилсульфонил-2,5-дигидропиррол-2-он в качестве промежуточного продукта дл синтеза 1,5-дифенил-3-оксиэтиламино-4-метилсульфонил-2,5-дигидропиррол-2-она, обладающего антиагрегатной активностью против тромбоцитов |
US5202344A (en) * | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
US5508300A (en) * | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
GB9803228D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
CA2371618A1 (en) * | 1999-04-28 | 2000-11-09 | Yuji Ishihara | Cyclic amide compounds, their production and use |
-
2002
- 2002-09-26 US US10/489,661 patent/US20050004180A1/en not_active Abandoned
- 2002-09-26 JP JP2003533929A patent/JP2005523238A/ja active Pending
- 2002-09-26 PL PL02370355A patent/PL370355A1/xx not_active Application Discontinuation
- 2002-09-26 CN CNA028195639A patent/CN1564685A/zh active Pending
- 2002-09-26 CA CA002463198A patent/CA2463198A1/en not_active Abandoned
- 2002-09-26 HU HU0402503A patent/HUP0402503A2/hu unknown
- 2002-09-26 US US10/255,494 patent/US6727275B2/en not_active Expired - Fee Related
- 2002-09-26 WO PCT/EP2002/010810 patent/WO2003030897A1/en not_active Application Discontinuation
- 2002-09-26 EP EP02800576A patent/EP1434577A1/en not_active Withdrawn
- 2002-09-26 KR KR10-2004-7004999A patent/KR20040048936A/ko not_active Application Discontinuation
- 2002-09-26 IL IL16064202A patent/IL160642A0/xx unknown
- 2002-09-26 CZ CZ2004442A patent/CZ2004442A3/cs unknown
- 2002-09-26 NZ NZ532018A patent/NZ532018A/xx unknown
- 2002-09-26 BR BR0212968-0A patent/BR0212968A/pt not_active Application Discontinuation
- 2002-09-26 RU RU2004109818/15A patent/RU2004109818A/ru not_active Application Discontinuation
- 2002-10-03 CO CO02089166A patent/CO5390075A1/es not_active Application Discontinuation
- 2002-10-03 AR ARP020103733A patent/AR036672A1/es not_active Application Discontinuation
-
2003
- 2003-12-31 US US10/750,247 patent/US6936633B2/en not_active Expired - Fee Related
-
2004
- 2004-03-30 MX MXPA04002982A patent/MXPA04002982A/es unknown
- 2004-04-01 BG BG108660A patent/BG108660A/xx unknown
- 2004-04-30 NO NO20041767A patent/NO20041767L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL370355A1 (en) | 2005-05-16 |
US6936633B2 (en) | 2005-08-30 |
WO2003030897A1 (en) | 2003-04-17 |
RU2004109818A (ru) | 2005-05-10 |
CO5390075A1 (es) | 2004-04-30 |
IL160642A0 (en) | 2004-07-25 |
US20040157914A1 (en) | 2004-08-12 |
NO20041767L (no) | 2004-04-30 |
MXPA04002982A (es) | 2004-07-15 |
BG108660A (en) | 2005-03-31 |
US6727275B2 (en) | 2004-04-27 |
EP1434577A1 (en) | 2004-07-07 |
BR0212968A (pt) | 2004-10-13 |
CN1564685A (zh) | 2005-01-12 |
US20030149081A1 (en) | 2003-08-07 |
HUP0402503A2 (hu) | 2005-03-29 |
JP2005523238A (ja) | 2005-08-04 |
CA2463198A1 (en) | 2003-04-17 |
NZ532018A (en) | 2004-12-24 |
KR20040048936A (ko) | 2004-06-10 |
US20050004180A1 (en) | 2005-01-06 |
CZ2004442A3 (cs) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036672A1 (es) | Derivados de pirrolidinona | |
CO5690638A2 (es) | Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen | |
HK1084024A1 (en) | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer | |
YU84791A (sh) | Biciklicni 1-aza-cikloalkalni | |
AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
MA28747B1 (fr) | Dérivés de pyridine | |
UY28121A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
LU91196I2 (fr) | Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO). | |
JP2008526999A5 (es) | ||
DE60330407D1 (de) | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung | |
UY26089A1 (es) | Inhibidores de la sorbitol deshidrogenasa | |
AR058347A1 (es) | Entidades quimias composiciones y metodos | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
PE20040531A1 (es) | Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen | |
PE20220252A1 (es) | Compuestos de pirrol | |
ES2176719T3 (es) | Derivados de benzopirano que tienen una accion antagonista de leucotrienos. | |
PE20040750A1 (es) | Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |